Cinaciguat

Cinaciguat (BAY 58-2667) is an experimental drug for the treatment of acute decompensated heart failure.

Cinaciguat
Clinical data
Routes of
administration
intravenous (?)
ATC code
  • none
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC36H39NO5
Molar mass565.710 g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

Mechanism of action

Cinaciguat activates the soluble guanylate cyclase (sGC) which is a receptor for nitric oxide. This increases biosynthesis of cyclic GMP, resulting in vasodilation.[1]

See also

  • Riociguat, another drug stimulating sGC, but with a different mechanism
  • PDE5 inhibitors act further downstream in the nitric oxide signalling pathway, reducing cyclic GMP degradation.

References

  1. Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel 2009



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.